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ANALYSIS OF TUMOR SPECIFIC PROTEIN EXPRESSION IN GLIOBLASTOMA 
MULTIFORME (GBMs) TUMORS-THROUGH IMMUNOHISTOCHEMISTRY 
 By 
 
 Amanda M. Wigand 
GBM tumors are the most aggressive and, unfortunately, the most fatal form of brain 
cancer. GBM tumors with isocitrate dehydrogenase-1 (IDH1) mutation being expressed, 
lead to higher survival rates in patients that also have full resection of the tumor and 
chemotherapy. Without this mutation, it is thought that tumors have a higher expression 
of the protein Basigin and O6-methylguanine-DNA-methyltransferase (MGMT) present, 
causing it to be more aggressive and less responsive to standard care. The objective of 
this study was to understand the correlation between IDH1 mutation presence and the 
expression of Basigin and MGMT. The expression of these proteins was observed in 
tissues sections from GBM tumors. Proteins were labeled with a fluorescent antibody 
and imaged with a confocal microscope. The tissue images were then analyzed using 
Imaris software. It was shown that there was a significant difference between the 
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Glioblastoma multiforme (GBM) tumors are the most common and aggressive 
form of brain tumor in humans1. Death from GBM tumors is associated with the rapid 
rate of tumor growth, which can double in size every two weeks. GBM tumors are 
classified as either primary or secondary tumors. Primary GBMs generally form in older 
individuals, and the tumors progress rapidly resulting in the quick onset of symptoms 
and relatively short patient survival times2. These primary tumor types are the most 
common and deadly form of GBMs. Secondary GBMs generally occur in people at age 
forty-five or younger and represent ten percent of all GBMs3. Secondary GBMs tend to 
grow at a slower rate and are more responsive to treatment, however they are, none-the-
less, deadly if not treated. GBM tumors appear heterogeneous in their composition, as 
they will contain several different substances, including cystic minerals, calcium 
deposits, blood vessels, and dead cells. Because of their location within the brain, GBMs 
rarely metastasize to other regions of the body. However, presence of tumor tissue 
within the brain results in significant morbidity as the tumor invades and crowds out 
normal brain tissue 2. 
The ability to distinguish between GBM tumors of differing severity is central 
to the efforts to develop novel therapies. For example, many GBM tumors over-
express DNA repair enzymes like O-6-methylguanine-DNA methyltransferase 
(MGMT), which makes them resistant to chemotherapy and radiotherapy treatments 4.  
MGMT does not play a role in tumor development, it is mainly utilized for tumor 
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maintenance. Identifying proteins associated with resistant GBM tumors is a necessary 
first step in the process of developing novel therapies. Currently, our work is focused 
upon three specific proteins known individually to play a significant role in the 









Cancer Development and GBMs 
The development of cancer in humans can occur in response to many different 
kinds of damage to DNA, including exposure to toxic substances, viruses, or radiation. 
In all cases, the main hallmark of cancer development is the abnormal proliferation of 
cells collectively, referred to as neoplasia. Tumors develop from normal cells in stages 
as the cancer develops an ever-increasing ability to proliferate. Thus, the terms 
hyperplasia, metaplasia, and dysplasia have been used to describe the increasing 
proliferative capacity, with dysplastic tumors being the most aggressive cancers5. 
Hyperplasia refers to tissues that appear normal but are growing inappropriately. 
Metaplasia refers to tissues that are still exhibiting functional characteristics, but 
demonstrate the overgrowth of one tissue or cell type over another. Lastly, cells or 
tissues that appear abnormal and are clearly growing in an uncontrolled fashion are 
referred to as dysplastic5. The multiple-hit hypothesis for tumor formation (also called 
the Knudson hypothesis) states that dysplastic tumors contain cells with two or more 
mutations to important growth regulatory genes6. For example, a mutation that 
inactivates a gene that normally suppresses cell growth (tumor suppressor genes) can 
result in a cell growing and dividing uncontrollably6. Such tumor suppressor genes act 
as brakes to prevent abnormal cell growth. Conversely, mutations that activate normally 
inactive genes or amplify genes that are not regularly transcribed, resulting in cell 
proliferation, are referred to as proto-oncogenes.  In this case, mutations to proto-
oncogenes can convert them to oncogenes resulting in the production of proteins that 
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are constitutively active and promote cell proliferation. The Knudson hypothesis 
proposes that cells generally require both the inactivation of tumor suppressor genes 
and the activation of proto-oncogenes to form dysplastic tumors5.  
Within GBM tumors exists a population of cells that play a central role in tumor 
progression. These so-called cancer stem cells (CSCs) are slow growing and possess 
properties of stem cells, including the ability for self-renewal. Like other stem cells, 
CSC appear to be resistant to chemotherapeutics, possess an enhanced ability to repair 
damage to DNA, and are able to regenerate tumors following surgical removal of the 
original tumor 
7
. Furthermore, CSC are able to divide without differentiating and thus 
can provide a reservoir for the formation of new tumors 8. It is unknown whether the 
CSCs are the cancer initiating cells of a GBM tumor, or whether they represent a 
population of dysplastic cells that have de-differentiated to form stem cell-like cells. 
It is widely accepted that brain tumors can arise from a number of different glial 
cell types such as, glial progenitor cells, astrocytes, or oligodendrocytes, giving rise to 
tumors of varying severity9. GBMs that arise from glia or other precursor cells within 
the central nervous system (CNS) cause their specific pathologies as the tumors 
proliferate in an uncontrolled fashion. A number of changes have been identified in 
GBM tumors, including either an insensitivity or oversensitivity to cell autonomous 
signals, or self-signaling, hypermethylation or hypomethylation of chromatin regions 
surrounding key cellular growth or apoptosis genes, and specific mutations within the 
DNA10. A particularly significant mutation found within GBMs and lower grade gliomas 
occurs to the Isocitrate dehydrogenase 1 gene (IDH1). Point mutations to the IDH1 gene 
can produce an arginine-to-histidine amino acid change at amino acid 132 of the IDH1 
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enzyme (called the IDH1 R132H mutant).This mutation leads to sensitivity to reactive 
oxidative species. Reactive oxidative species are a collection of molecules produced by 
normal cellular metabolism that can cause cellular damage. In its normal state, it has 
been shown that IDH1 may function to help maintain the redox state within the cell and 
promote cellular defense against oxidative damage11.  The point mutation to IDH 
resulting in IDH1 R132H produces an oncogene that has a role in oncogenesis and may 
be an important possibility for therapeutic interventions10.  
GBM tumors tend to experience changes in the expression profiles for many 
genes which confers a phenotype that resists treatment and promotes cancer growth; the 
enzyme O-6-methylguanine-DNA methyltransferase (MGMT) falls in this category. 
MGMT is a DNA repair enzyme that removes chemical adducts from damaged DNA, 
preventing future damage, specifically from the O6 guanine residue12. The 
chemotherapeutic drug Temozolomide (TMZ), which is the standard chemotherapy 
agent used to treat GBM tumors, functions by adding alkyl or methyl groups to the N7 
position of guanine, N3 position of adenine, and the O6 guanine residues4. TMZ induces 
DNA damage, most importantly to the O6 guanine residue, the most cytotoxic location, 
stimulating apoptotic processes that result in the death of the rapidly growing cells 
found within the tumor. However, when a tumor cell overexpresses the MGMT enzyme, 
such cancers can evolve resistance to alkylating therapeutic agents like TMZ13. 
Therefore, a comprehensive understanding of the expression patterns for DNA repair 
enzymes, such as MGMT, in patient tumors, is central in our efforts to effectively treat 
GBM patients 4. 
Primary vs. Secondary GBM 
Primary and secondary tumors are thought to arise from different populations 
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and are characterized by different genetic changes within each 9. More importantly, 
primary tumors tend to be more aggressive and arise in older populations, while 
secondary tumors are less aggressive and occur in younger populations14. Primary 
tumors often have genetic alterations including the loss of the proximal arm of 
chromosome 10 (called LOH 10p), amplification of epidermal growth factor receptor 
gene (EGFR) and Murine Double Minute-2 oncoprotein (MDM2) gene, and inactivating 
mutations to the PTEN tumor suppressor gene14. Primary tumors also develop rapidly 
after a short clinical history and with very little evidence of less malignant preceding 
tumors15. Consequently, these tumors are extremely aggressive in their growth and 
resistance to treatment, and result in a poor prognosis for patients14. 
Secondary GBMs area characterized by a loss of the distal arm of chromosomes 
19 and 22 (19q, 22q), and mutations in the TP53 tumor suppressor gene. Secondary 
GBMs are more likely to develop from slow growing and well-differentiated low-grade 
astrocytomas. These tumors have a tendency to slowly invade other brain tissues, 
develop into an anaplastic astrocytomas, and eventually form secondary GBMs15. The 
TP53 mutation is considered an early mutation in the sequence of tumor formation, as it 
occurs in low-grade, diffuse astrocytomas as well as in most secondary GBMs14. TP53 is 
commonly mutated in a number of different human cancer types as the p53 protein, 
which is produced as a product of the TP53 gene, is a master regulator of the cell cycle 
and is important for the suppression of tumor development. Inactivating mutations to 
TP53 generally involve a single base substitution, and subsequent loss of the remaining 
wild type allele16. TP53 mutations are known to be very diverse in their sequence 
context, position and structure, and generally result in a missense mutation causing a 
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single amino-acid change in the p53 protein16. Interestingly, TP53 mutations and IDH1 
mutations are generally both present within secondary GBMs 3. 
Morphological Characteristics of GBM tumors 
GBM tumor tissue is heterogeneous in nature and can vary widely in both the 
cellular and vascular forms. Analysis of tumor architecture is performed by 
histochemical analysis of biopsied tissues. Histological analysis of tumors is the gold 
standard utilized by pathologists to assess the ‘tumor grade’ of a patient. According the 
World Health Organization (WHO), a grade IV astrocytoma is classified as a GBM and 
will generally contain a variety of cell types, microvascular proliferation (MVP), 
endothelial hyperplasia and hypertrophy, glomeruloid vessels and cellular necrosis17. 
MVP is the formation of a new blood supply to the tumor and has been causally linked 
to other significant characteristics of GBMs, including hypoxia-induced gene 
expression changes and the expression of cytokines such as vascular endothelial 
growth factor (VEGF)17. MVP is linked to the appearance of necrosis within the tissue. 
All of these morphological conditions can be visualized using histochemical techniques 
to more accurately predict overall survival of a patient17. However, histochemical 
analysis is limiting because it does not provide information regarding the expression of 
particular oncogenes or tumor suppressors within the tumor. Because of the 
heterogeneity of cells in GBM tumors, the identification of particular cell types, 
oncogenes, and tumor suppressor proteins is critical for effective therapeutic 
approaches. Such an approach, if available, would give health care providers critically 
important information regarding tumor treatment and possibly improve patient 
outcomes. To this end, we propose to utilize immunohistochemical analysis of human 
tumors and attempt to correlate the known severity of human GBM tumors with the 
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expression of three cancer cell markers: IDH1-R132H, MGMT, and Basigin.  
IDH1  
 The human genome possesses five IDH genes that give rise to different isozymes 
of the IDH protein, including IDH1, IDH2, IDH3A, IDH3B and IDH3G18. In cells, the 
IDH1 and IDH2 proteins both function as homodimers by binding with an identical 
protein subunit to initiate catalytic activity. The three IDH3 isozymes form dimers 
composed of either two alpha subunits, or one beta and one gamma subunit. IDH 
proteins function within both the cytosol (IDH1) and mitochondria (IDH2 and IDH3) to 
generate reduced nicotinamide adenine dinucleotide phosphate, NADPH, from 
NADPH
+18. IDH1 to catalyze the oxidative decarboxylation of isocitrate to alpha-
ketoglutarate (α-kg) 11. IDH2 and IDH3 proteins function within the mitochondria in the 
Kreb cycle by converting isocitrate to α-KG and reducing Nicotinamide adenine 
dinucleotide NAD+ to NADH
11
. The Kreb cycle is utilized by cells to generate 
adenosine triphosphate molecules through different enzymatic reactions. 
The most common IDH mutation found in GBMs is an IDH1 point mutation that 
converts the arginine residue at position 132 to histidine, called IDH1 R132H 19. This 
IDH1 mutation is also found in other cancers including acute myelogenous leukemia 
(AML), cholangiocarcinoma, cartilaginous tumors, prostate cancer, papillary breast 
carcinoma, acute lympoblastic leukemia (ALL), angioimmunoblastic T-cell lymphoma, 
and primary myelofibrosis11. IDH1 R132H mutations are present within 55% to 80% of 
grade II and III gliomas and are commonly present within secondary GBMs. GBM 
patients that carry the IDH1 R132H mutation experience improved survival following 
maximal resection of the tumor 20. Thus, knowledge of the mutation status for IDH1 in 
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brain cancers can lead to a better prognosis for patients. The effect of the R132H 
mutation is the production of the oncometabolite 2-hydroxyglutarate (2-HG; see also 
figure 1) 21.  
 The production of 2-HG induces changes in DNA methylation pathways and 
gene expression in cell, ultimately, promoting tumorigensis. Known as the CpG island 
methylator phenotype (CIMP), 2-HG induced DNA methylation is an indirect result of 
the IDH R132H mutation. CIMP is correlated with widespread hypermethylation in 
genes at specific loci 22. It is currently unclear how the IDH1 mutation initiates tumor 
growth and lead to CIMP in any type of cancer 21. Even though mutant IDH1 is viewed 
as an oncogene, information about its presence within a tumor can be helpful as patients 
treated with Telozolomide (TMZ) and radiation can experience greatly improved 
survival times23. 
MGMT and Temozolomide 
MGMT is an enzyme that removes chemical adducts from DNA, thus preventing 
damage to the DNA. This DNA repair enzyme, when present in tumors, can reverse the 
DNA damaging effects of chemotherapeutics such as TMZ 12. Thus, increased levels of 
the MGMT enzyme correlate with poor responses to TMZ. Most cells express MGMT 
enzymes, and the expression of the MGMT gene can be induced by DNA damage 
24
.  
Interestingly, some cells will exhibit greatly reduced levels of the MGMT protein as a 
result of MGMT promoter methylation events
25
. In such cells, the reduction of MGMT 
enzyme levels allows for TMZ-induced DNA damage and subsequently apoptotic cell 
death. The expression level of MGMT effects the size of tumors.  MGMT promoter 
methylation and reduced MGMT protein tend to be smaller in size and respond more 
positively to treatment. In contrast, when the MGMT promoter is not methylated tumors 
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are larger due to the lack of damage to cellular DNA26.  
As mentioned previously, the primary chemotherapeutic agent utilized to treat 
GBM tumors is TMZ. TMZ induces the alkylation or methylation of DNA at the N7 
position of guanine, N3 position of adenine, and the O6 position of guanine. When the 
O6 guanine residue becomes methylated it constitutes nearly all of the activity of TMZ 
but is only five percent of the total adducts added to the DNA. The methylation of 
guanine causes a mismatch pairing with guanine and tyrosine, triggering apoptotic death 
of rapidly growing cells such as GBM tumor cells (Figure 2)
4
. The introduction of TMZ 
in 2007 for GBM patients resulted in the greatest improvement in patient survival ever 
observed for this deadly cancer 12. Unlike most chemotherapeutics, TMZ is readily 
absorbed through oral administration and can easily cross the blood brain barrier. Within 
the body, TMZ is converted to the active compound 5-(3-dimethyl-1-triazenyl) 
imidazole-4-carboxamide (MITIC), and the conversion of TMZ to MITIC is pH 
dependent (Figure 3) 
25
. MITIC’s main sites of methylation are the N7 position of 
guanine, the N3 position of adenine and the O6 position of guanine4. Cell cycle 
checkpoint regulators recognize this damage to the DNA and halt the cell cycle. 
However, the overexpression of MGMT enzymes can reduce the effectiveness of 
TMZ’s effects as the MGMT enzymes repair DNA modifications produced by TMZ 27. 
Therefore, information regarding the expression level of MGMT in tumors is central to 
predicting the effectiveness of TMZ treatment. DNA sequencing of tumor genomes has 
revealed that MGMT promoter cytosine methylation levels can predict responses to 
TMZ treatment. Non-methylated MGMT promoter results in elevated expression of the 
MGMT gene, and thus a reduced responsiveness to TMZ 24. Therefore, developing 
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methodologies to identify tumors that express elevated levels of MGMT is central to 
determining the potential effectiveness of TMZ treatment. Progression free survival 
(PFS) and overall survival (OS) have been shown to be superior with MGMT promoter 




Basigin is a transmembrane glycoprotein with many different cellular functions. 
Known by many different acronyms, including EMMPRIN and CD147, Basigin is 
involved in processes such as sexual reproduction, neural function, inflammation, and 
tumor invasion28. Tumors with increased Basigin expression correlate positively with an 
aggressive invasive phenotype 28. Elevated Basigin expression in tumors stimulates 
surrounding tissues to express vascular endothelial growth factor (VEGF), which 
promotes neoangiogenesis, or the formation and growth of new blood vessels 29. 
Additional evidence demonstrates that elevated Basigin stimulates the expression of 
matrix metalloproteinase (MMP) enzymes needed for remodeling of the extracellular 
matrix of the tissue surrounding the tumor 30. Basigin protein functions in a paracrine 
manner to stimulate surrounding tissues to produce other molecules needed by the tumor 
to grow and spread. Thus, stimulating other cells to remodel the extracellular matrix and  
surrounding tissue.  
It may seem counterintuitive that a transmembrane glycoprotein can function as 
a paracrine signaling molecule, but it is well established that Basigin can be released 
from the surface of tumor cells via microvesicle shedding (Figure 4). In fact, there has 
been an explosion of data demonstrating that most cells release some form of 
microvesicle (either membrane microvesicles or exosomes) that can stimulate 
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surrounding tissues to alter their activity 
31
. The release of microvesicles from tumors 
containing Basigin protein elevates the expression of metalloproteinase enzymes in 
surrounding cells and promotes remodeling of the extracellular matrix to allow for 
tumor growth and spread32. This phenomenon suggested that there must be a basigin 
receptor on cells, and Belton et. al., showed that the cell surface Basigin protein was 
shown to function as a receptor for soluble Basigin protein 33. In response to soluble 
Basigin, normal (non-cancerous) cells are stimulated via the p42/44 Map Kinase 
signaling pathway resulting in elevated expression and secretion of a number of MMP 
gene products. Therefore, aggressive cancers that express and release greater amounts of 
Basigin protein are able drive surrounding tissues to synthesize molecules that promote 
tumor survival. Finally, increased Basigin expression within tumor cells promotes the 
ability of cancer cells to survive chemotherapy directly. This appears to be a direct result 
of Basigin’s interaction with P-glycoprotein and ATP-binding casset transporters, or 
ABCG transporters that function to remove toxic compounds from cells and thus assist 
cell survival pathways in the presence of chemotherapeutic agents34. 
Normal human brain tissue expresses little to no Basigin protein, while brain 
tumors express elevated levels of Basigin34. Furthermore, patients with GBM tumors 
tend to struggle more with daily activities and general cognitive function when their 
cancer has higher Basigin levels. This evidence also correlates with reduced overall 
survival of patients and suggests that Basigin is a critical marker for tumor severity 
and patient outcomes 34. Based upon this evidence, we hypothesized that the severity 
of a particular GBM tumor correlates positively with the expression levels of Basigin 
and the DNA repair enzyme MGMT, and inversely with the expression of the IDH1 
R132H mutant metabolic enzyme. To test this hypothesis, human brain tissues from 
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GBM patients were analyzed for protein expression using immunohistological staining 
techniques. The data was collected by confocal microscopy, and quantitatively 


























While Basigin, MGMT, and IDH1 are all expressed in GBMs, it is not yet 
known how the levels of expression for each protein affect tumor aggressiveness and 
resistance to treatment. For this project, commercially available antibodies specific for 
the target proteins were utilized to identify relative expression levels for each in human 
tumor samples. GBM cell lines were used to demonstrate that the antibodies specifically 
recognize their target proteins using a standard immunoblotting approach. Paraffin 
embedded tumor samples were prepared for fluorescent immunohistochemistry and 
confocal microscopy to analyze the level of expression. It was expected that increased 
expression of Basigin and MGMT would correlate with more aggressive GBM tumors. 
While the IDH1 R132H mutation is not always present within primary GBMs (it is often 
seen within secondary GBMs), the presence of this mutation would benefit patient 
survival if the tumor were fully resected and treated with TMZ and radiation. 
Human GBM samples 
Glioblastoma samples were provided by the UP Health System- Marquette 
(UPHSM). The use of these tissues was approved by UPHSM Institutional Review 
Board (IRB) and the Northern Michigan University IRB. The preserved tissue was 
collected between 2003 and 2004, and patient information associated with the tumor 
samples was expunged from the records prior to use. The initial histological analysis of 
the tissues was performed in the Department of Pathology of UPHSM by Dr. John 
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Weiss. Dr. Weiss provided marking of malignant spots of Hematoxylin & Eosin (H&E) 
stained tissue sections. 
Human GBM Cell Lines 
U87MG IDH1 R132H mutant cell line was a kind gift from Horacio Soto at 
Geffen Cancer Center at UCLA. The U87MG, LN229, T98 (American Tissue Culture 
Collection Manassas, VA), and fibroblast cell line, MSU 1.1 from Michigan State 
University. Cell lines were grown in standard conditions of 37°C and 5% CO2 in 
complete media, Eagle’s minimal essential medium and Dulbecco’s Modified Eagle’s 
Medium (Lonza, Walkersville, MD) with 10% bovine serum (FBS) (Atlanta Biological, 
Atlanta, GA) and 1% Penicillin/Streptomycin/Amphotericin B (Gibco, CA) to 80% 
confluency in T-75 flasks. Cells were harvested using the trypsin-EDTA method 
(Versene, Lonza) and cells pelleted at 300x g. Cell pellets were washed and resuspended 
in growth media for replating in tissue cultureware at a ratio of 1/3. 
Immunoblotting and Antibodies 
Nearly confluent cell monolayers were washed with cold PBS and the cells lysed 
using a 1% NP-40 non-denaturing detergent buffer. Lysates were clarified by 
centrifugation (20,000xG, 10 minutes, 4°C) and the supernatant collected. Total protein 
concentration was determined using the bicinchoninic acid assay (BCA). 10mg of 
protein were loaded into the wells of a precast 4-15% SDS-polyacrylamide gels 
(BioRad) and resolved at 200volts for approximately 1 hour. The cellular proteins were 
transferred from the polyacrylamide gels by electroblotting onto PVDF membranes for 
10 hours at 100mA. PVDF membranes were treated with a solution of 5% non-fat dry 
milk (NFDM) dissolved in Tris-Buffered Saline containing 0.1% Tween20 (TBST). 
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Blocked membranes were incubated with the primary antibodies (Basigin 1:500, 
IDH1m-Dianova 3.33:1000, IDH1 wt 1:500, MGMT 1:500,) overnight at 4°C with 
shaking. Visualization of specific proteins was accomplished by staining with a goat 
anti-mouse horseradish peroxidase-labeled antibody (Thermo Scientific) for one hour 
followed by detection with enhanced chemiluminescence (Pierce Pico 
Chemiluminescence Reagent). Films were exposed to the blots for thirty seconds and 
five minutes (Five minute exposure images are figures 6-10). Images were obtained 
using a Kodak M35A X-OMAT Processor. 
The primary antibodies used in this study were as follows: mouse anti-IDH1 
(Origene Technologies, Rockville, MD), mouse anti- IDH1-R132H (Millipore, 
Darmstadt, Germany), mouse anti-MGMT (Thermo Fisher Scientific, United States), 
mouse anti- Basigin (Genetex), and mouse anti-human IDH1 R132H (Dianova, 
Germany). The following secondary antibodies were used: donkey anti-mouse 
Alexaflour 488 (Jackson ImmunoResearch, West Grove, PA) and donkey anti-mouse 
HRP (Thermo Fisher Scientific, United States). 
Histochemistry 
Paraffin embedded tumor samples were sectioned at 5μm and transferred to glass 
slide. Sections were deparaffinazed and rehydrated through graded series of xylene-
ethanol. The slides were stained with hematoxylin (Richard-Allen Scientific) and eosin 
(Richard- Allen Scientific) and then dehydrated through another ethanol-xylene graded 
series. Following the final xylene wash, the slides were mounted with Cytoseal 60 
(Richard-Allan Scientific) and a glass cover slip. Tissue slides were marked, regraded, 
and imaged by Dr. Weiss at UP Health System- Marquette. All tissue blocks that were 
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used in this study were confirmed to be GBM tumors. 
Immunostaining and confocal imaging 
Tissue sections were deparaffinized and rehydrated through graded series of 
xylene-ethanol and then washed in PBS three times for ten minutes each. Tissue sections 
were blocked with blocking buffer containing donkey serum (Jackson ImmunoResearch) 
for one hour. Afterwards, the tissues were incubated with the primary antibodies for 
Basigin, MGMT, IDH1 R132H, or IDH1 over-night at 4°C (Basigin 1:500, IDH1m-
Dianova 1:20, IDH1m- Millipore 1:500, IDH1 wt 1:50, MGMT 1:15). Sections were 
then incubated with donkey anti-mouse Alexaflour 488 secondary antibody (1:100) 
(Jackson ImmunoResearch) for one hour in the dark. A second PBS wash was done, 
three times for ten minutes each, and then ProLong Diamond Antifade Mountant with 
DAPI (Thermo Scientific) was used to cover slip the sections.  Fluorescence intensity of 
marked malignant spots were visualized with a confocal microscope (Olympus ix81 
FV100). 
For analysis of the confocal z-stack scans, the software Imaris (Bitplane, 
Zurich, Switzerland) was used. The software was used to highlight the surface area and 
intensity of the fluorescence of the nuclei and proteins being tagged. The intensity for 
each protein was adjusted and expression was determined through the binding of a 
protein to the nuclei (DAPI stain). 
Statistical Analysis 
 The effects of different protein expression in tumor samples from 5 patients 
were modeled using “linear mixed models” in R version 3.2.3 (R Core Team 2015)35. 
The package “lme4” was used for the analysis36. Two response variables were analyzed 
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in separate models: “area” (area of the expressed protein, in μm2; and “intensity”. 
Intensity is based on the fluorescent signal that is being emitted by the Alexafluor 488 
antibody. The fixed effect of primary interest was “protein” (4 levels), but “patient” was 
also included as random factor to account for variation in protein expression among 
subjects. The model was of the type where Y= protein + (1 | patient), which models a 
varying-intercept group effect using the variable “patient”. Least squares means (lsm 
package in R) and Tukey’s Method were used to estimate means and differences 
between means adjusted for variation among patients. Linear mixed models were used 
because the design was unbalanced (some proteins were not present in all patients), and 
the cells measured were not independent. Linear mixed models are able to model the 









Hematoxylin and Eosin Analysis 
H&E staining was conducted on the five different GBM tumors that were used 
in this study. These slides were initially examined and by Dr. Weiss at UPHSM and the 
boundaries between malignant and nonmalignant tissues were marked. The malignant 
portions of the tumor were then imaged on the Olympus laser confocal microscope at 
NMU. Images of these H&E stained slides are shown in Figure 5. Different forms of 
vascularity and cell formation can be seen throughout the malignant portions of the 
tissue (Figure 5A-E). 
Protein expression within GBM cell lines 
Immunoblotting of GBM cell lines with the antibodies used in this study are 
shown in Figures 6-10. Equivalent amounts of soluble protein for the five cell lines used 
were loaded in each lane of the immunoblots. The results demonstrate the presence of 
bands at the anticipated molecular weights for each of the proteins. The DNA repair 
enzyme MGMT was expressed by the T98 and MSU 1.1 cell lines, but was not detected 
in any other cell line (Figure 6). The cell surface glycoprotein Basigin was expressed 
within all lines and clearly demonstrated the presence of two glycosylated forms: a high 
glycosylated form at ~45-60kDa and a low glycosylated form at ~35 kDa (Figure 7). 
The IDH1 wild type enzyme was expressed within all cell lines used. The antibody 
specific for the wildtype IDH1 cannot distinguish between the R132H IDH mutant and 
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the wild type enzyme. Therefore, the protein sample from the U87MG R132H cell line 
shows a significant increase in the IDH1 protein as this cell line overexpresses the 
R132H protein (Figure 8).  The IDH1 R132H mutation was expressed within the U87 
mutant cell line and was not present in any other (Figure 9). Figure 10 is an immunoblot 
showing the relative expression for the housekeeping gene GAPDH to show the relative 
amounts of protein within the cell lysates. 
Protein Expression within GBM tissue samples 
 Figures 11-15 represent images from the immunohistochemistry experiments 
performed on tissue sections from five different human GBM tumor samples. These 
different tissue samples are shown in Figure 11 = Block 5625, Figure 12 = Block 3331, 
Figure 13 = Block 4946, Figure 14 = Block 10168, and Figure 15 = Block 8072). In 
each series of figures, the tissues were probed with the following antibodies: A = 
Basigin, B = IDH1 wild type, C =  IDH1 R132H (Millipore), D = IDH1 R132H 
(Dianova), E =  MGMT.  
All GBM tissues expressed the proteins Basigin, IDH1, IDH1 R132H, and 
MGMT (Fig11-15). The level of fluorescence within each slide varies in the photos, but 
can clearly be seen. It should be noted that the IDH1 mutations were imaged using two 
antibodies from different manufacturers (Dianova and Millipore) and the images using 
both antibodies are shown. Some of the tissue blocks were initially thought to lack 
expression of the IDH1 mutation using the Millipore antibody, but when reimaged using 




Analysis of Protein Expression in GBM Samples 
Figure 16 represents the quantitative data from the fluorescent images shown in 
figures 11-15. The fluorescent emission from each slide was quantified using the Imaris 
software package. For this work, the fluorescence from individual cells was measured on 
Imaris, and the mean values for each protein provided by Imaris were adjusted for the 
variation among patients. When the data set for protein area was being analyzed, there 
were variations among the data points. The log of each point was taken and averaged for 
the final data set. The Tukey Method, a statistical single-step comparison method, was 
used to compare the means of the proteins in question. These means were also adjusted 
for the variation among patients. There were significant differences in intensity mean 
between Basigin and IDH1 m (t ratio= 3.271, df= 493.80, P=0.006), IDH1 m and IDH1 
wt (t ratio= -2.679, df= 492.09, P=0.038), and IDH1 m and MGMT (t ratio=-2.830, df= 
492.15, P=0.025). No other pairs were significantly different. When the average for 
log10 of the area means were taken there were significant difference between Basigin 
and IDH1 wt (P=0.006) and IDH1 wt and MGMT (P=0.0188). 
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IDH1 And IDH1 R132H mutant expression in GBM 
 The use of the human cell lines for immunoblot analysis provided a method for 
demonstrating the specificity of the antibodies used later in the analysis of the human 
GBM tissues. For the anti-IDH1 antibodies, what was learned from this analysis was 
that the anti-IDH1 antibody that is designed to recognize the R132H point mutation 
was highly specific and did not detect the wild-type IDH1 protein in any of the cell 
lines used (Figure 9). This antibody detected 10ng of a recombinant IDH1 R132H 
peptide and the IDH1 R132H isoform overexpressed in the cell line. This cell line was 
a gift from Horacio Soto at Geffen Cancer Center at UCLA
39
. These cells overexpress 
this mutant IDH1 R132H isoform (which I will refer to as ‘IDH1m’) in a background 
of wild-type IDH1 produced by the cell. Both the wildtype and the mutant isoform 
possess identical molecular weights and could not be distinguished from each other 
without the use of monoclonal antibodies. Immunoblotting with the wild-type anti-
IDH1 antibody detected the IDH1 protein in all the cell lines, including the IDH1m 
isomer in the mutant cell line. This is consistent with the fact that this antibody 
recognizes an epitope that is shared in all forms of the IDH1 protein (mutant and wild-
type). Thus, in lane 2 of figure 8, the antibody produced a strong signal as it recognized 
epitopes on the over-expressed recombinant protein. Within human tissues, the 
presence of the R132H mutation leads to the production of the oncometabolite 2-
hydroxyglutarate (2-HG) and often results in the loss of the wild-type IDH1 allele 
10
. 
The presence of fluorescent signals on the same GBM tissues using both wildtype and 
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mutant IDH1 antibodies suggests that both isoforms are present within the tissues 
(Figures 11-16, panels B, C & D). However, it is also possible that some of the protein 
recognized by the wild-type antibody actually represents the IDH1m isoform. 
Unfortunately, clarification of this issue was outside of the technical ability in this 
study. Nonetheless, the immunoreactivity with the IDH1m antibody is highly specific, 
and the results from Figure 11-16 panel D clearly show the presence of this mutant 
isoform. The significance of this result is that this isoform is usually found in low-
grade brain tumors and secondary GBMs, and patients with this mutation experience a 
longer survival rate with full resection of the tumor and aggressive chemotherapy.  
Basigin expression in GBMs 
The cell surface glycoprotein named Basigin has recently been an area of 
interest as a cancer antigen
34
. Known also as extracellular matrix metalloproteinase 
inducer (EMMPRIN) or CD147, the expression of basigin protein in GBM tumors is 
generally very high
34
. Elevated Basigin levels correlate with increased angiogenesis, 
cell proliferation and cell invasion leading to more aggressive tumors with a more fatal 
diagnosis
37
. Immunostaining of the GBM tissues demonstrated a significant difference 
in the expression levels of Basigin and IDH1m, with IDH1m expression reduced in 
cells with elevated Basigin. This data supports our hypothesis that these two proteins 
are inversely correlated and may have separate and opposing effects in tumor growth. 
Further research is needed to show the exact correlation between the two proteins. If 
there is a decreased amount of Basigin being expressed when IDH1m is present, either 
in a heterozygous or homozygous fashion, this would help explain the reason why 
GBMs with this mutation respond to treatment. The decreased amount of Basigin 
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would not promote as much angiogenesis and cell proliferation, therefore forming a 
less aggressive and slower growing tumor.  
MGMT Expression 
Immunoblot analysis of the DNA repair enzyme MGMT within the human cell 
lines demonstrated that this protein is expressed in the GBM cell line T98 and the 
human fibroblast cell line MSU 1.1. A lack of MGMT expression in particular cells is 
commonly a result of MGMT promoter methylation status, as the promoter methylation 
silences MGMT gene expression 
40
. The cell lines LN229 and U87MG did not express 
MGMT protein suggesting that the MGMT promoters in these cell lines are 
methylated. To confirm this result, additional experiments would be necessary, 
including bisulfite DNA sequencing to demonstrate the methylation of cytosine 
residues within the MGMT promoter. Cells that maintain expression of the MGMT 
gene can repair DNA damaged by alkylating agents such as TMZ. Therefore, blocking 
MGMT production or function would enhance the effectiveness of chemotherapeutics 
like TMZ. Based upon the statistical analysis of the MGMT expression in GBM tissues 
(Tukey’s test), MGMT levels are significantly reduced in cells expressing of IDH1m. 
Once again, this pattern of protein expression supports the stated hypothesis that 
MGMT levels are inversely correlated with IDH1m expression levels. At this time, we 
cannot yet explain how the presence of IDH1 R132H enzyme affects expression levels 
of Basigin or MGMT, nor how it may alter tumor growth and repair.  
Protein Expression within Human GBM tumors 
There was variation within the protein expression in the GBM tissues samples. 
When observing the differences in mean intensity of each protein, there was a 
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significant difference between IDH1m and all other proteins. Basigin, IDH1wt, and 
MGMT were not significantly different from one another. Among the five patients, 
there was overall stronger fluorescent signal for Basigin, IDH1wt and MGMT. When 
examining the area of each protein in the tissues, there were significant differences 
between IDH1 wt and MGMT, and IDH1 wt and Basigin. Since this study was mainly 
comparing the difference of expression in IDH1 mutation and Basigin expression, it 
was surprising to find differences between IDH1 wt and other proteins. The difference 
between the mean intensity and area could be explained by the difference in 
measurement. Mean intensity is measuring the brightness of the secondary antibody 
and the area is measuring the size of the protein bound by the antibodies. This may not 
give the most accurate depiction of what is truly happening within the tumors.  
In future studies it would be best to utilize different primary antibodies that 
originate from different host animals. This would allow us to probe each tissue 
block with multiple antibodies simultaneously to allow for the measurement of 
protein expression in each cell of a tumor. This approach would allow for a more 
powerful statistical analysis of the correlation between protein expression, tumor 
growth and patient survival. 
CONCLUSION 
In conclusion, this study has shown that there is a difference among IDH1 
mutation expression and Basigin, IDH1 wt and MGMT. Further investigation on these 
findings is needed and a larger patient group should be used. Patient history may also 
be useful in future studies to assist in background knowledge of the patients. Having 
the background knowledge of patients may allow for more of a selective process when 
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choosing tumor blocks and allow for a control group (GBM with IDH1m and without). 
Finding more correlations between these proteins may lead to better treatments and 
more advantageous diagnoses leading to a longer overall survival, and possibly, better 
quality of life for GBM patients. This could be accomplished by increasing the amount 
of tumor suppressor gene mutations and oncogene overexpression that are tested for 
after tumor resection. Also, adding to the forms of treatment and possible 







Figure 1. Isocitrate dehydrogenase (IDH) enzyme function in human cells. This 
figure illustrates the role of the IDH enzymes in cellular metabolism in both the 
mitochondria and the cytoplasm of the cell. The enzyme IDH1 primarily functions in 
the cytoplasm of the cell where it is involved in the production of NADPH and  





Figure 2. Common temozolomide-induced DNA lesions appear on guanine 
and adenine. N7-methylguanine, N3-methyladenine and O6-methylguanine 
DNA adducts account for roughly 70%, 10% and 5% of these lesions 
respectively. The enzyme MGMT mediates removal of the O6-methylguanine 








Figure 3. Temozolomide is converted to MTIC within the body and contributes 
methyl or alkyl chemical groups on DNA. Adapted from Agarwala et al. The 




Figure 4. Microvesicles and exosomes are membrane vesicles released from 
cells to the extracellular space. Image adapted from Raposo & Stoorvogel J. Cell 
Biol. Vol. 200 No. 4 373–383 www.jcb.org/cgi/doi/10.1083/jcb.201211138 
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Figure 5A. H&E Staining from Block 5652. This image illustrates 
increased blood vessel growth (arrows) and formation and increased 
cell density within the sample. High vascularity is a common sign of 
GBM tumors and many tumors will develop their own blood supply 





Figure 5B. H&E Staining from Block 3331. This image shows 
high cell density on the left side of the image and necrosis (arrows) 
on the right where the arrows are located. Necrosis is a very common 





Figure 5C. H&E Staining from Block 4946. This image of a 
GBM tumor shows gemistocytic astrocytes (arrows) that are 
characterized by their swollen cytoplasmic mass. These types of 
astrocytes are present when there is scarring within the CNS tissue 





























Figure 5D. H&E Staining from Block 10168. This tissue is displaying 
glomeruloid vascularity, indicated by the arrows. This form of vasculature 
is conducive with angiogenesis and can signify the presence of elevated 































Figure 5E. H&E Staining from Block 8072. This GBM tissue is 
displaying high cell density and this is believed to be the outer area 






































Figure 11A. Immunofluorescence of basigin in block 5625. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and basigin 

























Figure 11B. Immunofluorescence of IDH1 wild type in block 5625. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
























Figure 11C. Immunofluorescence of IDH1 mutation in block 5625. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 

























Figure 11D. Immunofluorescence of IDH1 mutation in block 5625. 
The control image is showing the absence of the Dianova fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
























Figure 11E. Immunofluorescence of MGMT in block 5625. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and MGMT 

























Figure 12A. Immunofluorescence of Basigin in block 3331. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and Basigin 
























Figure 12B. Immunofluorescence of IDH1 wild type in block 3331. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
























Figure 12C. Immunofluorescence of IDH1 mutation in block 3331. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 

























Figure 12D. Immunofluorescence of IDH1 mutation in block 3331. 
The control image is showing the absence of the Dianova fluorescent 
antibody binding. The merged image is showing both DAPI staining and 

























Figure 12E. Immunofluorescence of MGMT in block 3331. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and MGMT 
























Figure 13A. Immunofluorescence of basigin in block 4946. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and basigin 























Figure 13B. Immunofluorescence of IDH1 wild type in block 4946. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 

























Figure 13C. Immunofluorescence of IDH1 mutation in block 4946. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
























Figure 13D. Immunofluorescence of IDH1 mutation in block 4946. 
The control image is showing the absence of the Dianova fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 mutation expression, along with the outlines of the cell bodies. 




















Figure 13E. Immunofluorescence of MGMT in block 4946. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and MGMT 
expression, along with the outlines of the cell bodies. 




















Figure 14A. Immunofluorescence of Basigin in block 10168. The 
control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
Basigin expression, along with the outlines of the cell bodies. 






















Figure 14B. Immunofluorescence of IDH1 wild type in block 10168. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 wild type expression, along with the outlines of the cell bodies. 






















Figure 14C. Immunofluorescence of IDH1 mutation in block 10168. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 mutation expression, along with the outlines of the cell bodies. 






















Figure 14D. Immunofluorescence of IDH1 mutation in block 10168. 
The control image is showing the absence of the Dianova fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 mutation expression, along with the outlines of the cell bodies. 





















Figure 14E. Immunofluorescence of MGMT in block 10168. The 
control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
MGMT expression, along with the outlines of the cell bodies. 





















Figure 15A. Immunofluorescence of Basigin in block 8072. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and Basigin 
expression, along with the outlines of the cell bodies. 





















Figure 15B. Immunofluorescence of IDH1 wild type in block 8072. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 wild type expression, along with the outlines of the cell bodies. 





















Figure 15C. Immunofluorescence of IDH1 mutation in block 8072. 
The control image is showing the absence of the secondary fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
























Figure 15D. Immunofluorescence of IDH1 mutation in block 8072. 
The control image is showing the absence of the Dianova fluorescent 
antibody binding. The merged image is showing both DAPI staining and 
IDH1 mutation expression, along with the outlines of the cell bodies. 























Figure 15E. Immunofluorescence of MGMT in block 8072. The control 
image is showing the absence of the secondary fluorescent antibody 
binding. The merged image is showing both DAPI staining and MGMT 





Figure 16A. Significant differences were found between the mean intensity of Basigin 
and IDH1 m (t ratio= 3.271, df= 493.80, P=0.006), IDH1m and IDHwt (t ratio=3.271, 
df=492.09, P=0.038), and IDH1m and MGMT (t ratio=2.830, df=492.15, P=0.025).  
No other pairs were found to be significantly different. 
 
 
Figure 16B. Using the log 10 of area, significant differences were found between 
Basigin and IDH1 wt (P=0.006) and IDH1wt and MGMT (P=0.0188). Means with the 
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